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Introduction {#sec1}
============

Acute lower respiratory tract infection (LRTI) is common in primary care [@bib1]. Antibiotic treatment is of limited benefit both overall and in subgroups at higher risk of an adverse course. Nevertheless, antibiotics are prescribed for most patients with LRTI [@bib2], [@bib3], [@bib4], [@bib5]. Primary analysis of the largest trial to date, the Genomics to combat Resistance against Antibiotics in Community-acquired LRTI (GRACE; <http://www.grace-lrti.org>) randomized placebo controlled trial (RCT), found no clear evidence of a clinically meaningful benefit from treatment with amoxicillin [@bib2]. A follow-up analysis that examined the benefit of amoxicillin in clinically defined subgroups of patients with LRTI who are most likely to be prescribed antibiotics (i.e. patients with green sputum or those with significant comorbidities) found no clear evidence of meaningful benefit from amoxicillin even in these subgroups [@bib3]. Only those patients with evidence of pneumonia on chest X-ray benefited from amoxicillin treatment [@bib6].

However, it is unclear whether patients infected with bacterial pathogens might selectively benefit from antibiotic treatment, and filling this evidence gap could help better target antibiotic prescribing in primary care. This secondary analysis of the GRACE RCT therefore aims to assess whether patients from whom potential bacterial pathogens are isolated receive benefit from amoxicillin treatment. In addition, we aimed to assess whether isolation of a viral pathogen and high levels of C-reactive protein (CRP), blood urea nitrogen (BUN), or procalcitonin (PCT) were associated with benefit from treatment with amoxicillin [@bib7], [@bib8], [@bib9].

Methods {#sec2}
=======

Data {#sec2.1}
----

The details of the GRACE RCT have been described in detail elsewhere [@bib2]. In summary, non-pregnant adults presenting to primary care with acute cough, in whom pneumonia was not suspected, were recruited between November 2007 and April 2010 by primary care physicians in 16 networks across 12 European countries (Belgium, England, France, Germany, Italy, The Netherlands, Poland, Spain, Slovakia, Slovenia, Sweden, and Wales). Patients who did not consume antibiotics in the month before consultation were randomized to receive either an antibiotic (amoxicillin 1 g) or a placebo three times daily for 7 consecutive days. All patients were asked to complete a symptom diary daily until their symptoms had settled (up to a maximum of 28 days). The diary recorded the severity of cough, phlegm, shortness of breath, wheezing, runny nose, chest pain, muscle ache, headache, disturbed sleep, feeling unwell, fever, and interference with daily activities. Symptoms were scored on a 7-point scale (0: normal/not affected, 1: very little problem, 2: slight problem, 3: moderately bad, 4: bad, 5: very bad, 6: as bad as it could be) [@bib10]. For each patient, a nasopharyngeal swab was taken on the day of presentation. This sample was then analysed using bacterial and viral polymerase chain reaction analysis. We tested for both bacterial pathogens (*Streptococcus pneumoniae*, *Haemophilus influenza*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Bordetella pertussis*, *Legionella pneumoniae*) and *v*iral pathogens (rhinovirus, influenza virus, coronavirus, respiratory syncytial virus, human metapneumovirus, parainfluenza virus, adenovirus, polyomavirus, bocavirus) [@bib11]. Samples with a pathogen present, either bacterial or viral, were referred to as confirmed infections. Samples in which a bacterial pathogen was detected were referred to as bacterial infections. If no viral pathogens were present in these samples, they were referred to as purely bacterial infections. Samples in which a viral pathogen was detected were referred to as viral infections. If no bacterial pathogens were present in these samples, they were referred to as purely viral infections. Samples in which both a bacterial and a viral pathogen were detected were referred to as combined infections. Note that these categorizations are not mutually exclusive. Within 24 hours of presentation to the GP, a venous blood sample was obtained. CRP and BUN were measured using the conventional immunoturbidimetric method. PCT was measured using a rapid sensitive assay [@bib11]. We defined an elevated CRP, PCT, and BUN as the top 25% of measurements in our patient population (referred to as high CRP, high PCT, and high BUN, respectively).

Main outcomes {#sec2.2}
-------------

Symptom duration: The primary outcome was the duration of symptoms rated moderately bad or worse by the patient (score 3 or above) following the initial presentation (in days) [@bib12].

Symptom severity: A secondary outcome was symptom severity, calculated as the mean diary score for all symptoms on days 2--4 (rated by the patient). This time frame was selected because before day 2 antibiotics will have had little chance to provide benefit, and after day 4 the overall symptom severity is less than moderately bad [@bib12].

Illness deterioration: An additional secondary outcome was illness deterioration, defined as a return to the physician with worsening symptoms, new symptoms, new signs or illness requiring admission to hospital within 4 weeks of the initial consultation (documented through a notes review) [@bib13].

Analysis {#sec2.3}
--------

We fitted a Cox regression model for symptom duration (allowing for censoring), a linear regression model for symptom severity, and a logistic regression model for illness deterioration [@bib14], [@bib15], [@bib16]. All analyses controlled for severity of symptoms at baseline and included an interaction term between a particular subgroup (in the studied subgroup or not) and treatment (amoxicillin or placebo). This interaction term was used to assess whether the effectiveness of amoxicillin treatment varied by the subgroup. Similar models, excluding the interaction term, were fitted for patients in the selected subgroup.

The subgroups of interest were patients with a confirmed, bacterial, purely bacterial, viral, purely viral, or combined infection. We were also interested in subgroups with a high CRP, high BUN, or high PCT. Subgroups were not mutually exclusive.

Ethics approval {#sec2.4}
---------------

The study was approved by ethics committees in all participating countries. The competent authority in each country also gave their approval. Patients who fulfilled the inclusion criteria were given written and verbal information on the study and provided written informed consent. The GRACE RCT is registered with EudraCT (2007-001586-15), UKCRN Portfolio (ID 4175), ISRCTN (52261229), and FWO (G.0274.08N).

Results {#sec3}
=======

In total, 2058 patients (out of 2061) that did not consume antibiotics in the month before consultation were randomized. Symptom duration and symptom severity were reported for 87% (1793/2058) and 88% (1804/2024) of patients, respectively. Illness deterioration (or no deterioration) was documented in 98% (2024/2058) of whom 18% (355/2024) experienced illness deterioration. The vast majority of those with illness deterioration represented reconsultation with new or worsening symptoms. Sample size information for subgroup analyses is presented in [Fig. 1](#fig1){ref-type="fig"} .Fig. 1Patient flow chart.

Symptom duration {#sec3.1}
----------------

No subgroups were identified that were significantly more likely to benefit from amoxicillin for the duration of symptoms (in days) rated moderately bad or worse ([Table 1](#tbl1){ref-type="table"} ).Table 1Symptom duration[a](#tbl1fna){ref-type="table-fn"} in patients consulting in primary care with LRTI treated with amoxicillin versus placeboMedian symptom duration (IQR)Interaction term[b](#tbl1fnb){ref-type="table-fn"} (95% CI)p-ValueHazard ratio for subgroup[b](#tbl1fnb){ref-type="table-fn"} (95% CI)p-ValueAmoxicillinPlaceboWhole cohort (*n* = 1804)6 (3--11)7 (3--13)1.06 (0.96 to 1.17)0.268Confirmed infection (*n* = 1163)6 (3--11)7 (4--11)0.92 (0.75 to 1.14)0.4351.03 (0.91 to 1.16)0.673Bacterial infection (*n* = 392)6 (3--16)7 (4--14)0.96 (0.76 to 1.23)0.7671.03 (0.83 to 1.27)0.821Purely bacterial infection (*n* = 209)5 (3--16.5)9 (5--17)1.10 (0.80 to 1.51)0.5541.13 (0.84 to 1.53)0.421Viral infection (*n* = 883)6 (3.5--11)7 (3--11)0.92 (0.75 to 1.12)0.3941.01 (0.88 to 1.17)0.884Purely viral infection(*n* = 700)6 (3--11)7 (3--11)0.98 (0.80 to 1.21)0.8551.04 (0.89 to 1.23)0.599Combined infection (*n* = 183)7 (4--14)6 (3.5--11)0.83 (0.59 to 1.15)0.2500.89 (0.65 to 1.21)0.450High PCT (*n* = 436)6 (4--13)7 (4--13)1.06 (0.84 to 1.34)0.6021.09 (0.89 to 1.33)0.423High BUN (*n* = 441)6 (3--13)7 (3--13)0.96 (0.76 to 1.21)0.7230.99 (0.81 to 1.22)0.956High CRP (*n* = 421)6 (4--11)7 (4--12)1.03 (0.81 to 1.31)0.7971.06 (0.86 to 1.31)0.567[^1][^2][^3]

Symptom severity {#sec3.2}
----------------

Patients with a purely bacterial infection benefitted from amoxicillin treatment ([Table 2](#tbl2){ref-type="table"} ; interaction term −0.25 (95% CI −0.49 to 0.00); the mean symptom severity score was 0.26 (95% CI −0.48 to −0.03) points lower compared with patients on placebo ([Table 2](#tbl2){ref-type="table"}).Table 2Symptom severity[a](#tbl2fna){ref-type="table-fn"} (standard deviation) in patients consulting in primary care with LRTI treated with amoxicillin versus placeboAmoxicillinPlaceboInteraction term[b](#tbl2fnb){ref-type="table-fn"} (95% CI)p-ValueDifference for subgroup[b](#tbl2fnb){ref-type="table-fn"} (95% CI)p-ValueWhole cohort (*n* = 1793)1.59 (0.95)1.70 (1.01)−0.07 (−0.15 to 0.01)0.065Confirmed infection (*n* = 1158)1.71 (0.99)1.82 (1.02)0.03 (−0.13 to 0.19)0.720−0.06 (−0.16 to 0.04)0.221Bacterial infection (*n* = 390)1.56 (0.95)1.87 (1.05)−0.09 (−0.28 to 0.10)0.330−0.14 (−0.31 to 0.03)0.108Purely bacterial infection (*n* = 207)1.44 (0.95)1.90 (1.09)−0.25 (−0.49 to 0.00)0.048−0.26 (−0.48 to −0.03)0.027Viral infection (*n* = 880)1.78 (1.00)1.83 (1.01)0.12 (−0.03 to 0.28)0.119−0.02 (−0.13 to 0.10)0.801Purely viral infection (*n* = 697)1.80 (1.01)1.83 (1.01)0.09 (−0.07 to 0.25)0.251−0.02 (−0.15 to 0.11)0.755Combined infection (*n* = 183)1.69 (0.94)1.84 (1.00)0.10 (−0.15 to 0.36)0.423−0.01 (−0.27 to 0.25)0.943High PCT (*n* = 434)1.67 (0.98)1.87 (1.14)−0.09 (−0.27 to 0.09)0.326−0.13 (−0.30 to 0.04)0.144High BUN (*n* = 439)1.45 (0.93)1.52 (0.98)−0.03 (−0.21 to 0.16)0.782−0.08 (−0.23 to 0.07)0.294High CRP (*n* = 420)1.88 (1.00)2.03 (1.03)−0.07 (−0.25 to 0.12)0.473−0.12 (−0.29 to 0.06)0.201[^4][^5][^6]

Illness deterioration {#sec3.3}
---------------------

Patients with a bacterial infection benefited from amoxicillin in terms of illness deterioration ([Table 3](#tbl3){ref-type="table"} ; interaction term 0.47 (95% CI 0.27 to 0.82), OR 0.46 (95% CI 0.29 to 0.75)).Table 3Illness deterioration[a](#tbl3fna){ref-type="table-fn"} in patients consulting in primary care with LRTI treated with amoxicillin versus placeboAmoxicillinPlaceboInteraction term[b](#tbl3fnb){ref-type="table-fn"} (95% CI)p-ValueOdds ratio for subgroup[b](#tbl3fnb){ref-type="table-fn"} (95% CI)p-ValueWhole cohort (*n* = 2024)162/1019193/10050.80 (0.63 to 1.00)0.051Confirmed infection (*n* = 1292)100/652137/6400.58 (0.36 to 0.95)0.0290.67 (0.50 to 0.88)0.005Bacterial infection (*n* = 420)30/18967/2310.47 (0.27 to 0.82)0.0070.46 (0.29 to 0.75)0.002Purely bacterial infection (*n* = 222)21/10032/1220.91 (0.46 to 1.79)0.7920.75 (0.40 to 1.40)0.364Viral infection (*n* = 1000)72/51498/4860.66 (0.41 to 1.04)0.0750.64 (0.46 to 0.90)0.010Purely viral infection (*n* = 802)63/42563/3771.12 (0.69 to 1.81)0.6390.87 (0.59 to 1.27)0.464Combined infection (*n* = 198)9/8935/1090.26 (0.11 to 0.59)0.0010.24 (0.11 to 0.53)\<0.001High PCT (*n* = 481)39/24859/2330.62 (0.36 to 1.06)0.0790.55 (0.35 to 0.86)0.010High BUN (*n* = 473)40/23545/2381.15 (0.67 to 1.99)0.6050.88 (0.55 to 1.41)0.593High CRP (*n* = 478)41/23949/2391.03 (0.60 to 1.75)0.9270.80 (0.51 to 1.27)0.350[^7][^8][^9]

Patients with a combined infection treated with amoxicillin were less likely to experience illness deterioration ([Table 3](#tbl3){ref-type="table"}; interaction term 0.26 (95% CI 0.11; 0.59), OR 0.24 (95% CI 0.11 to 0.53)), with 32% (95% CI 23 to 41%) of patients receiving placebo experienced illness deterioration compared with only 10% (95% CI 4 to 16%) of patients receiving amoxicillin ([Fig. 2](#fig2){ref-type="fig"} ).Fig. 2Interaction between amoxicillin treatment (versus placebo) and having a combined infection (versus not having one): estimates and 95% CI.

Discussion {#sec4}
==========

We found no clear evidence of clinically meaningful benefit in terms of symptom duration from amoxicillin treatment in patents consulting in primary care with LRTI and from whom we isolated potential bacterial pathogens, viral pathogens, or identified mixed viral/bacterial infections. However, amoxicillin treatment did reduce symptom severity among patients with a purely bacterial infection, and did reduce the risk of illness deterioration in patients with a combined infection, but this effect was not seen among those with a purely bacterial infection.

Previous analyses from this GRACE trial of amoxicillin versus placebo in patients presenting with acute LRTI in primary care found that amoxicillin provided little benefit, both overall and in patients aged 60 and above. In fact, amoxicillin treatment was even associated with slight harm, in that more patients experienced side effects than were prevented from experiencing illness deterioration [@bib2]. A secondary subgroup analysis found that only those patients with significant comorbidities (mostly asthma or chronic obstructive pulmonary disease) benefitted from amoxicillin treatment in terms of reduced symptom severity between days 2 and 4 after first consulting in primary care. However, there was no benefit in terms of symptom duration or odds of illness deterioration, suggesting questionable clinical significance of the modest statistical short-term benefits of amoxicillin treatment in this subgroup [@bib3].

The secondary subgroup analysis presented here has found that patients with a purely bacterial infection benefit from amoxicillin in terms of reduced symptom severity, and that patients with a combined infection benefit from amoxicillin in terms of a reduced chance of illness deterioration. Although the benefit from amoxicillin treatment in those infected only by potential bacterial pathogens is of questionable clinical significance and has only borderline statistical significance, the effect in the combined infection group was an almost 20% reduction in the probability of illness deterioration.

We only found clear evidence of benefit (with p-values below 0.01) from amoxicillin treatment in the group of patients who had a bacterial infection. Given that the amoxicillin treatment is on average ineffective in patients with a purely bacterial infection, the effect of antibiotics in patients with a bacterial infection is driven by the effect in those patients with a combined infection. Assuming that this effect was not a result of chance, it may be biologically plausible: viral infections may predispose to secondary bacterial infections by causing mucosal damage or inflammation, lead to a longer or more severe illness course, and thus make these patients more likely to benefit from amoxicillin [@bib17], [@bib18], [@bib19]. However, the number of patients with a combined infection (9.6%; 199/2056) who could potentially benefit from antibiotic treatment indicates that the clinical impact of developing prediction rules or point of care tests for such patients is limited: 50 patients would have to be tested with a range of bacterial and viral diagnostic tests to identify five who have a combined infection, and all of these would have to be treated for one individual to benefit. Not only would such a policy need to be shown to be cost-effective in the short term, but the potential medicalization of illnesses (by signalling to the population that people with LRTI need to be tested) would have to be considered. Neither symptom duration nor symptom severity were clearly affected by amoxicillin treatment, and the odds of illness deterioration was influenced by amoxicillin treatment only in a very specific subgroup. The potential benefits of amoxicillin treatment should therefore be balanced against side effects, such as diarrhoea, nausea, or skin rash and the long-term risk of antibiotic resistance [@bib20]. Thus, most of these patients should probably not be prescribed an antibiotic, and/or clinicians could consider using a delayed antibiotic prescription to avoid inappropriate use of antibiotics [@bib21]. Nevertheless, it is important to be aware of the potential harm caused by under-treatment of a combined infection, so all patients must be given clear advice about when to reconsult.

Strengths and limitations {#sec4.1}
-------------------------

The findings from this study are applicable to European primary care clinical practice, as patient recruitment took place in 16 networks across 12 European countries. Some of the subgroups we studied were small, increasing risk of a Type II error. The subgroup with combined bacterial and viral infection was also not specified in advance, which increases the risk of a 'false positive' result (type I error) from multiple comparisons, and thus the results should be interpreted with caution. Similarly, the impact of amoxicillin on symptom severity among patients with a purely bacterial infection was of borderline significance, and was also of doubtful clinical importance. In contrast, the impact of amoxicillin treatment on reducing the risk of illness deterioration in patients with a bacterial infection, and in patients with a combined infection, was highly statistically significant.

Conclusion {#sec5}
==========

We found no clear evidence of benefit from amoxicillin treatment in adults presenting to primary care with LRTI for symptom severity or duration, irrespective of aetiology or biomarker test results. Amoxicillin treatment does reduce the risk of illness deterioration when both a viral and a bacterial pathogen are isolated. However, point of care testing to target antibiotic prescribing only to those with a combined bacterial and viral infection is unlikely to be a cost-effective.
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[^1]: BUN, blood urea nitrogen; CRP, C-reactive protein; IQR, interquartile range; LRTI, lower respiratory tract infection; PCT, procalcitonin.

[^2]: Calculated as the median (IQR) number of days with symptoms rated moderately bad or worse by the patient following the initial presentation.

[^3]: Estimates controlled for baseline symptom severity; values \<1 favour amoxicillin.

[^4]: BUN, blood urea nitrogen; CRP, C-reactive protein; LRTI, lower respiratory tract infection; PCT, procalcitonin.

[^5]: Calculated as the mean (standard deviation) diary score for all symptoms on days 2--4 (rated by the patient).

[^6]: Estimates controlled for baseline symptom severity; negative values favour amoxicillin.

[^7]: BUN, blood urea nitrogen; CRP, C-reactive protein; LRTI, lower respiratory tract infection; PCT, procalcitonin.

[^8]: Defined as a return to the physician with worsening symptoms, new symptoms, new signs, or illness requiring admission to hospital within 4 weeks of the initial consultation (determined through a notes review).

[^9]: Estimates controlled for baseline symptom severity; values \<1 favour amoxicillin.
